Hepatocardial syndrome in patients after ST-segment elevation myocardial infarction. GEFEST study
- 5 August 2026
- journal article
- Published by Media Sphere Publishing Group in Russian Journal of Preventive Medicine
- Vol. 29 (7)
Abstract
Objective. To investigate the clinical and laboratory changes, specifically focusing on liver function tests, echocardiographic parameters, as well as cognitive and emotional status, and to assess the incidence of cardiovascular events over a period of 12 months in elderly patients diagnosed with hepatocardial syndrome after ST-elevation myocardial infarction (STEMI), in the settings of standard cardiac therapy. Materials and methods. A prospective cohort comparative study was conducted, involving 537 patients aged 60 years or older (median age 68 [64; 73] years), who were evaluated no later than 6 months after a STEMI event. Two comparable groups were established through stratified selection based on sex, age, left ventricular ejection fraction (LVEF), and the grade of hepatic dysfunction: the main study group (n=269) and the control group (n=268). Patients in the main study group received ademetionine in addition to standard cardiac therapy, while those in the control group received standard therapy only. The primary endpoints included changes in alanine aminotransferase (ALAT), gamma-glutamyl transpeptidase (GGTP), and albumin levels at 6 months. Secondary endpoints included changes in LVEF, validated questionnaires scores (Montreal Cognitive Assessment Scale, Hospital Anxiety and Depression Scale, and Multidimensional Assessment of Fatigue), and the frequency of recurrent myocardial infarction, stroke, and cardiovascular mortality within 12 months. Statistical analyses were performed using the t-test, Mann—Whitney test, Pearson’s χ² test, and Bonferroni-corrected Cox regression for primary outcomes (p<0.0167). Results. In the main study group, a significant decrease in ALT levels was observed at 6 months, with a reduction of 41.8% (from 56.8±16.4 to 33.1±11.6 U/L), and a decrease in GGTP by 49.6% (from 78.4±24.6 to 39.5±14.8 U/L); albumin levels increased by 17.2% (from 34.2±4.6 to 40.1±5.0 g/L). All changes were statistically significant (p0.05). The increase in LVEF in the main group was 4.4% (p<0.001), while the control group showed a minimal increase of 0.8% (p=0.068). The incidence of cardiovascular events within 12 months was 5.9% in the main group versus 12.7% in the control group (p=0.006). According to Cox regression analysis, ademetionine therapy was independently correlated with a reduced risk of cardiovascular events (HR=0.51; 95% CI 0.33—0.79; p<0.001). Conclusions. Among elderly patients who have experienced ST-segment elevation myocardial infarction, there are observable slight improvements in liver function tests and left ventricular ejection fraction following standard therapy. The use of ademetionine is associated with more pronounced improvements in laboratory, instrumental, and clinical outcomes, warranting further investigation in randomized clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Hepatic Mechanisms of Myocardial Infarction: A New Perspective in Metabolic Dysfunction‐Associated Fatty Liver DiseaseJournal of the American Heart Association, 2025
- Noninvasive Hemodynamic Characterization of Cardiohepatic Syndrome in the Cardiac Intensive Care UnitJournal of the American Heart Association, 2025
- Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021BMC Cardiovascular Disorders, 2025
- Cardiovascular disease and metabolic dysfunction-associated steatotic liver disease: pathophysiology and diagnostic aspectsEuropean Journal of Preventive Cardiology, 2025
- Hepatic Biomarker Abnormalities in the Cardiac Intensive Care UnitJACC: Advances, 2025
- Effect of Real-Time Continuous Glucose Monitoring Versus Flash Glucose Monitoring on Glycemic Control in Adults with Type 1 Diabetes Mellitus: A Systematic Review and Meta-AnalysisMetabolic Syndrome and Related Disorders, 2024
- Biomarkers of cardiohepatic syndrome in the cardiac intensive care unitEuropean Heart Journal, 2024
- The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysisAnnals of Medicine, 2024
- Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapiesJournal of Hepatology, 2023
- Detection of bipolar disorder in the prodromal phase: A systematic review of assessment instrumentsJournal of Affective Disorders, 2023